Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07092865 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
A Phase 2 study of Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
- 20
- Study locations
NCT07092865: Recruiting Phase 2 study of Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline.
NCT07092865 is a Phase 2 study of Respiratory Syncytial Virus Infections that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 184 participants, below the 1,083-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07092865, a Phase 2 study of Respiratory Syncytial Virus Infections, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
Primary Outcome
RSV-A neutralizing titers are given as GMTs and are expressed as Estimated Dilution 60 (ED60). GMT is calculated by taking the anti-log of the mean of the log titer transformations.
Conditions Studied
Interventions
- BIOLOGICAL Adjuvanted RSVPreF3 vaccine
Study Locations (20)
Other
- GSK Investigational Site - Giessen
- GSK Investigational Site - Milan
- GSK Investigational Site - Milan
- GSK Investigational Site - Pavia
- GSK Investigational Site - Siena
- GSK Investigational Site - Aichi
Missouri
- GSK Investigational Site - St Louis
- GSK Investigational Site - St Louis
Queensland
- GSK Investigational Site - Birtinya
- GSK Investigational Site - Herston
Ontario
- GSK Investigational Site - London
- GSK Investigational Site - Toronto
Kentucky
- GSK Investigational Site - Lexington
Nebraska
- GSK Investigational Site - Omaha
New York
- GSK Investigational Site - New York
Pennsylvania
- GSK Investigational Site - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2027-07-16 |
| Phase | Phase 2 |
What NCT07092865 shows while recruiting
NCT07092865 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 1,083-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 1 intervention - of which Adjuvanted RSVPreF3 vaccine is the first listed.
NCT07092865 names 20 study sites across 12 states, led by Other, Missouri, Queensland.
Frequently Asked Questions
What is clinical trial NCT07092865 about?
NCT07092865 is a clinical study titled "A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant". This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
What is the current status of trial NCT07092865?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2025-08-06. Estimated completion is 2027-07-16.
What conditions does trial NCT07092865 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT07092865?
The interventions under investigation include: Adjuvanted RSVPreF3 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07092865?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07092865 being conducted?
This trial has 20 study locations across Kentucky, Missouri, Nebraska, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07092865's enrollment target sits among peer trials
184 14th of 21 higher than 8 of 21 other Respiratory Syncytial Virus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
RECRUITING · Phase 2
-
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
COMPLETED · Phase 2
-
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
COMPLETED · Phase 2
-
A Study of BLB-201 RSV Vaccine in Infants and Children
RECRUITING · Phase 1
-
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
RECRUITING · Phase 3
-
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI